ProSomnus Secures $38 Million Strategic Investment from Catalio Capital Management to Scale Smart Sleep Medicine™
ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy® and pioneer in Smart Sleep Medicine™, today announced a strategic investment from Catalio Capital Management, L.P. to accelerate the global expansion of its technology-enabled sleep health platform.
